Certain A Shares of CABIO Biotech(Wuhan) Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-DEC-2023.
December 18, 2023
Share
Certain A Shares of CABIO Biotech(Wuhan) Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-DEC-2023. These A Shares will be under lockup for 1464 days starting from 16-DEC-2019 to 19-DEC-2023.
Details:
The company's controlling shareholder Wuhan Alking Biological Engineering Co., Ltd. and actual controller, Yi Dewei committed that within 36 months since the date of listing of the present shares, there will not be no transfers nor entrustment of shares to any third party nor repurchase by the Company. If, within 6 months after the issuer's listing, the closing price of the shares is lower than issuance price for 20 consecutive trading days or if trading price is lower than issuance price after 6 month from listing, lock-up period will be automatically extended for another 6 months. If there is any case of dividends, bonus shares, capitalization of capital reserve and other similar cases, issue price will be adjusted according to ex-dividend and ex-interests. After the expiry of the lock-up period (including the extended lock-up period), the parties promise that yearly transfer of shares made by them will not exceed 25% of the holding, both direct and indirect, held by the present parties. After 6 months from rescindment, there will not be more transfers of shares, either direct or indirect. If any of the parties were to resign within 6 months from the present IPO, neither direct nor indirect holdings might be transferred or sold for 18 months since the date of rescinding. If the parties resign within 7 to 12 months after the IPO, neither direct nor indirect holdings might be transferred or sold for 12 months since the date of rescinding.
The Shareholders Beiyou Limited, Hangzhou Yuanchi Investment Partnership (Limited Partnership) and Wuhan Jiayihe Management Consulting Center (Limited Partnership), Shareholders Hubei Light Industrial Products Import and Export Co., Ltd. and Changhong (Shanghai) Investment Center (Limited Partnership), Indirect shareholders Su Shize and Wang Huabiao, Directors, supervisors, and management personnel indirectly holding shares in the Company, Ye Dewei, Wang Huabiao, Du Bin, Wang Zhiming, Ma Tao, Li Xiangyu and Wu Yujun and Core management personnel, Shang Yun, Lu Shuhuan and Xiao Min committed that within 12 months since the date of listing of the present shares, there will be no transfers nor entrustment of shares to any third party nor repurchase by the Company.
Cabio Biotech Wuhan Co Ltd is a China-based company principally engaged in biotechnology business. The Company is mainly engaged in the research and development, production and sales of polyunsaturated fatty acids arachidonic acid (ARA), algal oil docosahexaenoic acid (DHA) and sialic acid (SA), and natural beta-carotene products. Its products are mainly used in infant formula food, dietary supplements, nutritional health food and formula food for special medical purposes. The Company integrates industrial strain-oriented optimization technology, fermentation fine control technology, and efficient separation, purification and preparation technology, and provides nutrient products and innovative solutions for customers in the global nutrition and health field through sustainable microbial synthesis and manufacturing methods. The Company mainly conducts its business in domestic and overseas markets.